Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 225,206,970 papers from all fields of science
Search
Sign In
Create Free Account
ARN-810
Known as:
SERD ARN-810
, Selective Estrogen Receptor Degrader ARN-810
An orally available, nonsteroidal selective estrogen receptor degrader (SERD), with potential antineoplastic activity. Upon oral administration, SERD…
Expand
National Institutes of Health
Create Alert
Alert
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Selective estrogen receptor degraders with novel structural motifs induce regression in a tamoxifen-resistant breast cancer xenograft.
S. Govek
,
C. Bonnefous
,
+17 authors
N. Smith
Bioorganic & Medicinal Chemistry Letters
2019
Corpus ID: 58604491
2015
2015
Abstract P1-13-01: Phase I study of ARN-810, a novel and potent oral selective estrogen receptor degrader, in postmenopausal women with metastatic estrogen receptor positive (ER+), HER2- breast…
A. Bardia
,
M. Dickler
,
+10 authors
J. Baselga
2015
Corpus ID: 76014659
Background: Evidence that ER can signal in both ligand-dependent and independent manner in endocrine resistant breast cancer (BC…
Expand
2015
2015
Validation of target engagement using 18F-fluoroestradiol PET in patients undergoing therapy with selective estrogen receptor degrader, ARN-810 (GDC-0810)
Yingbing Wang
,
G. Ulaner
,
+7 authors
U. Mahmood
2015
Corpus ID: 58066487
2015
2015
Abstract 5053: Discovery of GDC-0810 a novel, non-steroidal selective estrogen receptor degrader with robust activity in pre-clinical models of endocrine-resistant breast cancer
James D. Joseph
,
S. Govek
,
+21 authors
J. Hager
2015
Corpus ID: 78722854
Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA The majority of breast cancers express estrogen…
Expand
2015
2015
Abstract 1864: Selective estrogen receptor degrader (SERD) activity in ESR1 mutant models
Wei Zhou
,
R. Blake
,
+16 authors
L. Friedman
2015
Corpus ID: 71073562
The majority of breast cancers express and rely on ERα for tumor growth, thus endocrine therapy is the mainstay of ER-positive…
Expand
2013
2013
Abstract OT3-2-07: Phase I study of ARN-810, a novel selective estrogen receptor degrader, in post-menopausal women with locally advanced or metastatic estrogen receptor positive breast cancer
I. Mayer
,
A. Bardia
,
+10 authors
C. Arteaga
2013
Corpus ID: 71645779
Background: Modulation of estrogen synthesis or its receptor activity represents the treatment of choice for postmenopausal women…
Expand
2013
2013
PERBEDAAN HASIL BELAJAR SISWA MENGGUNAKAN MODEL PEMBELAJARAN KOOPERATIF TIPE THINK TALK WRITE (TTW) DENGAN MODEL PEMBELAJARAN KONVENSIONAL (CERAMAH) PADA STANDART KOMPETENSI MENGGUNAKAN ALAT-ALAT…
Lamcihur Kaloko
2013
Corpus ID: 116802175
Penelitian ini menggunakan metode eksperimen.Populasi dalam penelitian ini adalah seluruh siswa kelas X SMK Teknik Rekayasa Sinar…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE